AKT1 and breast carcinoma: Breast cancer studies further revealed that knockdown of MAP3K1 in the context of PIK3CA mutations enhances Akt phosphorylation, leading to decreased cellular sensitivity to Akt inhibitors (Li C. et al., 2022), suggesting a complex regulation of drug resistance by a network of gene interactions.